Filings
Finds words inside filing documents. Searching InMed Pharmaceuticals Inc.'s filings · 76 documents indexed.
9 documents · 32 matches
-
INM InMed Pharmaceuticals Inc. 10-K 2022-09-23
Item 9A. Controls and Procedures
material weakness and is committed to a strong Internal Control over Financial Reporting (ICFR) environment. Management has designed and implemented14 matches in this document -
INM InMed Pharmaceuticals Inc. 8-K 2025-06-13
Item 4.01. Changes in Registrant’s Certifying Accountant
material weakness resulted in certain material audit adjustments in the year ended June 30, 2022 related to the presentation of pre-funded1 match in this document -
INM InMed Pharmaceuticals Inc. 10-K 2026-09-09
Item 1A. Risk Factors
material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination6 matches in this document -
INM InMed Pharmaceuticals Inc. 10-K 2025-09-23
Item 1A. Risk Factors
material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination6 matches in this document -
INM InMed Pharmaceuticals Inc. 10-Q 2026-11-03
Item 6. Exhibits 32
reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls;1 match in this document -
INM InMed Pharmaceuticals Inc. 10-Q 2026-05-06
Item 6. Exhibits 36
reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls;1 match in this document -
INM InMed Pharmaceuticals Inc. 10-Q 2026-02-11
Item 6. Exhibits 31
reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls;1 match in this document -
INM InMed Pharmaceuticals Inc. 10-Q 2025-11-06
Item 6. Exhibits 30
reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls;1 match in this document -
INM InMed Pharmaceuticals Inc. 10-Q 2025-05-12
Item 6. Exhibits 34
reporting in accordance with applicable regulatory requirements, and (ii) fully remediate any material weakness identified with respect to such internal controls;1 match in this document
Page 1 of 1 · 9 documents